The main purpose of an OLE in general is extended safety information, not efficacy confirmation.
OLE efficacy data can possibly be helpful on the side for potential approval. In our case imo it will need support from full subgroup plus genetic analysis correlations to provide some objective biomarker results that OLE patients really may benefit from A2-73. I doubt VERY MUCH the KOL advise Missling has mentioned about an OLE study taking the place of a RCT confirmatory P3 trial.
I think for these reasons the MAA filing may well slip into 2025 by the same pattern of missed catalyst expectations that Missling is by now well known for!
Market Data 
Markets 
